Ascendis Pharma A/S Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Royalty Pharma's revenue, earnings per share and valuation.

Royalty Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S.

Analyst Recommendations

This is a summary of current ratings for Ascendis Pharma A/S and Royalty Pharma, as reported by MarketBeat.com.

Ascendis Pharma A/S presently has a consensus target price of $187.6667, suggesting a potential upside of 51.12%. Royalty Pharma has a consensus target price of $51.8750, suggesting a potential upside of 24.55%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Royalty Pharma.

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 2.5% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Royalty Pharma's net margins, return on equity and return on assets.

Summary

Ascendis Pharma A/S beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Ascendis Pharma A/S and Genmab A/S's net margins, return on equity and return on assets.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ascendis Pharma A/S and Genmab A/S's revenue, earnings per share (EPS) and valuation.

Genmab A/S has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ascendis Pharma A/S and Genmab A/S, as provided by MarketBeat.

Ascendis Pharma A/S presently has a consensus price target of $187.6667, indicating a potential upside of 51.12%. Genmab A/S has a consensus price target of $42.1429, indicating a potential upside of 20.48%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Genmab A/S.

Summary

Genmab A/S beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Risk and Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Horizon Therapeutics Public and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics Public and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Horizon Therapeutics Public and Ascendis Pharma A/S, as reported by MarketBeat.

Horizon Therapeutics Public presently has a consensus target price of $111.3636, suggesting a potential upside of 19.09%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 51.12%. Given Ascendis Pharma A/S's higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Horizon Therapeutics Public.

Summary

Horizon Therapeutics Public beats Ascendis Pharma A/S on 10 of the 13 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Profitability

This table compares CureVac and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Insider & Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares CureVac and Ascendis Pharma A/S's gross revenue, earnings per share (EPS) and valuation.

CureVac has higher earnings, but lower revenue than Ascendis Pharma A/S.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for CureVac and Ascendis Pharma A/S, as provided by MarketBeat.com.

CureVac presently has a consensus price target of $58.3333, indicating a potential downside of 43.94%. Ascendis Pharma A/S has a consensus price target of $187.6667, indicating a potential upside of 51.12%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than CureVac.

Summary

Ascendis Pharma A/S beats CureVac on 5 of the 9 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Profitability

This table compares Ascendis Pharma A/S and Catalent's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Ascendis Pharma A/S and Catalent, as provided by MarketBeat.

Ascendis Pharma A/S currently has a consensus target price of $187.6667, indicating a potential upside of 51.12%. Catalent has a consensus target price of $125.1250, indicating a potential upside of 12.74%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Catalent.

Institutional and Insider Ownership

97.8% of Catalent shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Catalent's top-line revenue, earnings per share and valuation.

Catalent has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Summary

Catalent beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Alnylam Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Ascendis Pharma A/S has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Ascendis Pharma A/S and Alnylam Pharmaceuticals, as reported by MarketBeat.com.

Ascendis Pharma A/S currently has a consensus price target of $187.6667, suggesting a potential upside of 51.12%. Alnylam Pharmaceuticals has a consensus price target of $166.4118, suggesting a potential upside of 19.70%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Alnylam Pharmaceuticals.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Summary

Ascendis Pharma A/S beats Alnylam Pharmaceuticals on 9 of the 14 factors compared between the two stocks.